July 29 - Humana reported second-quarter results on Wednesday that beat Wall Street estimates on an adjusted earnings-per-share basis while its spending on medical services tracked the company’s expectations. Despite the upside on profit and revenue, Humana trimmed its net profit forecast for the year and its stock fell in pre-market trading.
The insurer said quarterly adjusted earnings were $7.61 per share, above analysts’ consensus of $7.22 per share. Net revenue for the quarter rose 26.2% to $40.87 billion, topping forecasts of $40.61 billion.
Humana reported a quarterly medical cost ratio - the share of premiums used to pay for medical care - of 91.2%. The company said this level was consistent with its expectations across both new and existing members. Analysts had expected a ratio of 91.19%, using data compiled by LSEG.
On the guidance front, Humana maintained its annual adjusted profit-per-share forecast of at least $9. However, the company lowered a separate net profit forecast to at least $6.52 per share from a prior projection of at least $8.36 per share. The revision accompanied a roughly 9% decline in Humana shares in pre-market trading.
Investors had been raising expectations for the insurer sector after peers, including larger rival UnitedHealth, raised their outlooks and demonstrated stronger cost control. In that context, Humana’s updated net profit guidance and the market reaction highlight ongoing investor sensitivity to profitability and cost trends among major insurers.
Humana emphasized membership momentum in its Medicare Advantage business. The company said it saw a 23% increase in enrollments in its individual Medicare Advantage plans during the quarter and reaffirmed its annual membership growth expectations for both Medicare and Medicaid products.
Context on Medicare Advantage
Privately managed Medicare Advantage plans - a core business for Humana serving people aged 65 and older and people with disabilities - have faced pressure from rising medical costs over the past three years and tighter reimbursement rates. Those pressures have prompted some insurers to scale back or exit underperforming markets. Humana, by contrast, has been expanding enrollment of members even as some major peers retreat from parts of the Medicare Advantage market.
Market reaction and investor focus
The combination of an earnings beat and a lowered net profit estimate illustrates the mixed signals investors are weighing: stronger-than-expected top-line growth and adjusted profits, but downward revisions to certain profit metrics and persistent cost pressures in the Medicare Advantage business.
Humana’s results and guidance will remain of particular interest to market participants focused on health insurers, Medicare Advantage dynamics, and the broader healthcare sector’s ability to manage rising medical costs.